YME2 Antibody

What is the optimal fixation method for immunodetection of YME2 protein in yeast cells?

When detecting YME2 protein in yeast cells, the fixation method significantly impacts antibody binding efficiency. For optimal results, use a two-step fixation protocol: first, treat cells with 3.7% formaldehyde for 20 minutes at room temperature, followed by permeabilization with 0.1% Triton X-100 for 10 minutes. This approach preserves the native conformation of YME2's complex domain architecture, including both the matrix-facing RNA recognition motif (RRM) and the intermembrane space-located AAA+ domain . For experiments requiring higher sensitivity, a methanol-acetone (1:1) fixation at -20°C for 10 minutes may provide better epitope accessibility, particularly when targeting the transmembrane domain between residues 287-305.

How can I verify YME2 antibody specificity in my experimental system?

Verifying antibody specificity for YME2 requires multiple validation approaches:

• Genetic validation: Compare antibody staining/signal between wild-type and Δyme2 knockout strains. A genuine YME2 antibody will show signal in wild-type cells but not in knockout cells.

• Epitope competition assay: Pre-incubate the antibody with purified YME2 protein or the specific peptide used for immunization before probing samples. Signal reduction indicates specificity.

• Western blot validation: Confirm single-band detection at the expected molecular weight (~65-70 kDa for full-length Yme2).

• Cross-reactivity testing: Test antibody against related AAA+ domain proteins to ensure specificity, particularly important when working with YME2 homologs across fungal species .

What immunoprecipitation conditions are most effective for studying YME2 protein complexes?

YME2 forms high molecular weight complexes containing multiple copies of the protein, as demonstrated by BN-PAGE analysis showing complexes of approximately 1250 kDa (similar to dimeric complex V) . For effective immunoprecipitation:

• Buffer composition: Use a gentle lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1% Digitonin or 0.5% n-Dodecyl β-D-maltoside (DDM), and protease inhibitor cocktail.

• Crosslinking option: For capturing transient interactions, consider using a membrane-permeable crosslinker like DSP (dithiobis[succinimidylpropionate]) at 1-2 mM for 30 minutes prior to lysis.

• Antibody coupling: Covalently couple YME2 antibodies to protein A/G beads using dimethyl pimelimidate to prevent antibody leaching during elution.

• Control for specificity: Always include parallel IPs with non-specific IgG and perform in Δyme2 strains to identify non-specific interactions .

This approach has been validated for studying YME2 interactions with components of the mitochondrial protein export machinery such as Mdm38 and Mba1 .

How can I generate domain-specific YME2 antibodies to distinguish between matrix and intermembrane space functions?

Generating domain-specific antibodies requires careful epitope selection based on YME2's complex topology:

• Domain-specific antigen design:

  • For RRM domain (matrix-facing): Target unique sequences within residues 120-280, avoiding the conserved RNP1 and RNP2 motifs if cross-reactivity with other RRM-containing proteins is a concern.

  • For AAA+ domain (IMS-facing): Select peptides from regions outside the Walker A and B motifs (which show conservation with other AAA+ proteins).

• Validation methodology:

  • Express truncated YME2 constructs (matrix domain only or IMS domain only) and test antibody recognition.

  • Perform submitochondrial fractionation to confirm domain accessibility (matrix proteins accessible after outer membrane permeabilization; IMS proteins requiring inner membrane disruption).

• Epitope mapping confirmation:

  • Create point mutations at key residues (e.g., Y242A in RNP1 or K393A in Walker A) and verify altered antibody recognition patterns .

This domain-specific approach allows investigation of YME2's dual functionality in RNA recognition (matrix side) and potential ATPase activity (IMS side).

What are the optimal conditions for detecting YME2's association with mtDNA nucleoids and MIOREX complexes using antibody-based approaches?

Detecting YME2's associations with both mtDNA nucleoids and MIOREX complexes requires specialized immunofluorescence and biochemical approaches:

• For nucleoid co-localization:

  • Fixation: Use 1% paraformaldehyde to preserve nucleoid integrity.

  • DNA counterstaining: Apply DAPI at 1 μg/ml or Picogreen.

  • Microscopy: Super-resolution techniques (STED or SIM) are recommended due to the small size of nucleoids.

  • Controls: Co-stain with established nucleoid markers (e.g., Abf2 in yeast).

• For MIOREX complex associations:

  • Sample preparation: Use gentle solubilization with digitonin (1.2%) to preserve large complexes.

  • Gradient analysis: Apply samples to 10-30% sucrose gradients and analyze fractions by Western blot.

  • Co-immunoprecipitation: Perform sequential IPs using antibodies against YME2 followed by known MIOREX components.

  • Proximity labeling: Consider APEX2 or BioID fusion to YME2 for in vivo proximity detection .

• Data analysis:

  • Quantify co-localization using Pearson's or Manders' coefficients.

  • For dynamic studies, implement FRAP (Fluorescence Recovery After Photobleaching) with fluorescently tagged YME2 to measure residence time at nucleoids.

How can I use antibodies to study the Walker motif mutations' effects on YME2 complex formation and function?

Walker motif mutations significantly impact YME2 complex formation, with Walker B mutations showing stronger effects than Walker A mutations . To study these effects:

• Conformational antibody generation:

  • Develop antibodies that specifically recognize the ATP-bound or nucleotide-free states of the AAA+ domain.

  • Use purified recombinant YME2 variants (WT, K393A, D522A) as immunogens under different nucleotide conditions.

• Structural integrity assessment:

  • Perform limited proteolysis followed by antibody detection to map conformational changes.

  • Apply native PAGE with gradient gels (3-12%) to resolve different oligomeric states.

  • Use BN-PAGE combined with Western blotting to track complex formation differences between wild-type and Walker mutants (K393A, D522A, and K393A/D522A) .

• Quantitative analysis protocol:

  • Apply quantitative immunoprecipitation assays to measure differences in subunit association.

  • Compare wild-type and mutant forms using identical antibody concentrations.

  • Develop ELISA or proximity-based assays to measure complex formation efficiency.

The Walker B mutation (D522A) shows more severe defects in complex formation than the Walker A mutation (K393A), while the double mutant (K393A/D522A) demonstrates almost complete abolishment of complex formation .

What are the best approaches for quantifying YME2 protein levels in different mitochondrial subcompartments?

Accurate quantification of YME2 across mitochondrial subcompartments requires:

• Submitochondrial fractionation protocol:

  • Outer membrane: Generate mitoplasts using digitonin (0.1-0.2 mg/mg protein).

  • Inner membrane vs. matrix: Use osmotic shock followed by sonication and sucrose gradient separation.

  • Verify fraction purity using established markers: Tom20 (OM), cytochrome c (IMS), Cox4 (IM), and Hsp60 (matrix).

• Quantitative western blotting optimization:

  • Use fluorescently-labeled secondary antibodies rather than chemiluminescence for better linearity.

  • Include recombinant YME2 protein standards (5-100 ng) on each gel for absolute quantification.

  • Apply three technical replicates with densitometric analysis and normalization to multiple loading controls.

• Advanced microscopy quantification:

  • Implement ratiometric imaging with reference proteins for each compartment.

  • Use structured illumination microscopy (SIM) to spatially resolve the single-spanning transmembrane topology.

  • Apply FRET-based approaches to measure proximity to known marker proteins in each subcompartment .

How can I design experiments to investigate the genetic interactions between YME2 and the mitochondrial protein export machinery using antibody-based techniques?

YME2 exhibits negative genetic interactions with MDM38, MBA1, and OXA1, components of the mitochondrial protein export machinery . To investigate these interactions:

• Epistasis analysis using antibodies:

  • Generate single and double deletion strains (Δyme2, Δmdm38, Δyme2Δmdm38, etc.).

  • Perform immunoprecipitation with antibodies against remaining components.

  • Compare protein complex composition and stoichiometry between strains.

  • Use proximity labeling with BirA-YME2 fusion proteins in different genetic backgrounds.

• Co-localization studies:

  • Implement multi-color immunofluorescence to track spatial relationships.

  • Apply stimulated emission depletion (STED) microscopy for higher resolution.

  • Quantify co-localization coefficients in wild-type vs. mutant backgrounds.

• Translation-dependent dynamics:

  • Use pulse-chase experiments with radioactive methionine labeling followed by immunoprecipitation.

  • Track newly synthesized mitochondrial proteins using YME2 antibodies in combination with antibodies against Mdm38, Mba1, or Oxa1.

  • Implement ribosome profiling with YME2 immunoprecipitation to identify mRNAs associated with YME2 complexes .

What controls and validation steps are essential when using phospho-specific antibodies to study potential regulatory modifications of YME2?

Though not explicitly mentioned in the search results, AAA+ domain proteins are often regulated by phosphorylation. For phospho-specific YME2 antibody applications:

• Essential controls table:

• Kinase/phosphatase manipulation experiments:

  • Identify candidate kinases using bioinformatic prediction tools.

  • Test antibody reactivity after overexpression or inhibition of predicted kinases.

  • Compare reactivity across growth conditions known to alter mitochondrial protein biogenesis.

• Functional validation:

  • Correlate phosphorylation status with complex formation efficiency.

  • Examine phosphorylation changes during mitochondrial stress responses.

  • Determine if phosphorylation impacts interactions with MDM38, MBA1, or OXA1 .

How can I develop a multiplexed immunoassay to simultaneously detect YME2 and its interacting partners in different genetic backgrounds?

Developing a multiplexed detection system requires:

• Antibody compatibility testing:

  • Test combinations of primary antibodies from different host species (rabbit anti-YME2 with mouse anti-MDM38, etc.).

  • Validate specificity using knockout controls for each target protein.

  • Optimize antibody concentrations to ensure balanced signal intensities.

• Multiplex platform selection and optimization:

  • Microfluidic-based systems: Optimize for minimal sample requirement (5-10 μg mitochondrial protein).

  • Bead-based multiplexing: Conjugate antibodies to spectrally distinct beads.

  • Planar arrays: Spot antibodies in defined patterns on functionalized glass slides.

• Data analysis workflow:

  • Implement internal normalization controls for each protein.

  • Develop standardized quantification methods across genetic backgrounds.

  • Apply statistical approaches suited for compositional data analysis.

• Validation strategy:

  • Compare results with traditional single-plex Western blots.

  • Verify patterns in genetic interaction strains (Δyme2, Δmdm38, Δyme2Δmdm38) .

  • Confirm with orthogonal methods (mass spectrometry-based quantification).

What are the most effective strategies for epitope mapping YME2 antibodies to determine recognition of specific functional domains?

Comprehensive epitope mapping for YME2 antibodies should address the protein's complex domain architecture:

• Peptide array approach:

  • Generate overlapping 15-20 amino acid peptides spanning the entire YME2 sequence.

  • Arrange in microarray format for high-throughput screening.

  • Include known functional motifs (RNP1, RNP2, Walker A, Walker B) as separate spots.

  • Test antibody binding under both native and denaturing conditions.

• Truncation/deletion mapping:

  • Create series of N- and C-terminal truncations preserving domain boundaries.

  • Express domain-specific constructs (matrix domain, transmembrane region, IMS domain).

  • Include point mutations at key functional residues (Y242A in RNP1, K393A in Walker A) .

• Hydrogen-deuterium exchange mass spectrometry:

  • Compare hydrogen-deuterium exchange patterns with and without antibody binding.

  • Map protected regions to identify conformational epitopes.

  • Correlate with predicted structural features from AlphaFold models .

• Cross-reactivity profiling:

  • Test against YME2 homologs from related fungal species.

  • Assess recognition of other RRM or AAA+ domain-containing proteins.

  • Use results to predict conservation of recognized epitopes.

How can I develop a high-throughput screening assay using YME2 antibodies to identify compounds that modulate its interaction with mitochondrial ribosomes?

Developing such a screening platform requires:

• Assay design options:

  • FRET-based assay: Label YME2 antibody and ribosomal protein antibodies with compatible fluorophores.

  • AlphaScreen approach: Conjugate YME2 antibody to donor beads and ribosomal antibodies to acceptor beads.

  • Split-luciferase complementation: Fuse fragments to YME2 and ribosomal components with antibody-based detection.

• Validation controls:

  • Positive control: Known conditions that enhance interaction (e.g., ATP depletion).

  • Negative control: Genetic disruption (Δyme2 or ribosomal component mutations).

  • Dynamic range validation: Titration of components to establish signal windows.

• Screening implementation:

  • Primary screen: Identify hits that modulate YME2-ribosome association.

  • Counter-screen: Filter compounds affecting YME2 complex formation.

  • Validation: Confirm hits using orthogonal methods (co-IP, BN-PAGE).

• Functional validation pipeline:

  • Assess effects on mitochondrial translation using pulse labeling.

  • Examine phenotypic consequences in genetic interaction backgrounds (Δmdm38, Δmba1) .

  • Investigate mechanism through structure-activity relationship studies.

How should I interpret contradictory results between immunofluorescence and biochemical fractionation studies of YME2 localization?

Contradictory results between techniques may arise from methodological limitations:

• Common causes of discrepancies:

  • Fixation artifacts: Certain fixatives may alter the conformation or accessibility of YME2 epitopes.

  • Antibody accessibility: The single-spanning transmembrane topology of YME2 may result in differential epitope exposure across techniques.

  • Extraction conditions: Harsh biochemical fractionation may disrupt YME2's association with nucleoids or MIOREX complexes .

• Resolution strategies:

  • Implement multiple fixation methods and compare results.

  • Use epitope-tagged YME2 variants alongside antibodies for validation.

  • Apply super-resolution microscopy to refine subcellular localization.

  • Perform gentle fractionation with multiple detergent conditions.

• Reconciliation approach:

  • Consider dynamic distribution models where YME2 may redistribute between subcompartments.

  • Examine localization under different metabolic conditions.

  • Implement live-cell imaging with fluorescently tagged YME2 to resolve dynamic behavior.

  • Use proximity labeling approaches (APEX2, BioID) to map the local environment of YME2.

What methodological modifications are needed when adapting YME2 antibody protocols from yeast to mammalian cell models studying potential homologs?

Adapting protocols for mammalian homologs requires:

• Homology assessment and epitope conservation:

  • Conduct sequence alignment between yeast YME2 and potential mammalian homologs.

  • Focus on conserved functional domains (RRM, AAA+) for antibody selection.

  • Consider generating new antibodies against mammalian-specific sequences when divergence is high.

• Protocol modifications table:

• Validation approach:

  • Use siRNA/shRNA knockdown to confirm specificity.

  • Implement CRISPR/Cas9 knockout cell lines as negative controls.

  • Express yeast YME2 in mammalian cells to test cross-reactivity directly.

• Species-specific considerations:

  • Account for potential post-translational modifications unique to mammalian systems.

  • Consider tissue-specific expression patterns when working with whole organisms.

  • Adjust extraction conditions for different mitochondrial membrane compositions.

How can I resolve antibody cross-reactivity issues when studying YME2 in the context of other AAA+ domain-containing proteins?

AAA+ domains are highly conserved, creating potential cross-reactivity challenges:

• Cross-reactivity assessment workflow:

  • Test against purified recombinant AAA+ proteins.

  • Evaluate signal in genetic deletion strains for YME2 and related proteins.

  • Perform peptide competition assays with sequences from YME2 and potential cross-reactive proteins.

  • Implement epitope mapping to identify unique recognition regions.

• Antibody purification strategies:

  • Deplete cross-reactive antibodies using affinity columns with related AAA+ proteins.

  • Perform positive selection using unique YME2 peptides.

  • Consider monospecific antibody isolation from polyclonal sera.

• Alternative detection approaches:

  • Develop detection strategies targeting non-AAA+ regions of YME2.

  • Use epitope-tagged YME2 variants in combination with tag-specific antibodies.

  • Implement mass spectrometry-based targeted proteomics for absolute specificity.

• Experimental design adjustments:

  • Include additional controls when working in contexts with multiple AAA+ proteins.

  • Design experiments that can distinguish between YME2 and cross-reactive signals.

  • Use orthogonal methods to confirm key findings when cross-reactivity cannot be eliminated .